ALNY compared with XPO: revenue, margins and what each company keeps, and the suppliers and customers both name

ALNYAlnylam Pharmaceuticals, Inc.

Mkt capRevenueRevenue

XPOXPO, Inc.

Mkt capRevenueRevenue

Compare

ALNYAlnylam Pharmaceuticals, Inc.

XPOXPO, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ALNY

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±11.1%▼−25.13%×2.26

Q2 FY26—▼−28.31%—

Q1 FY26—▲+2.76%—

Feb 12 '26—▼−4.28%—

XPO

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±8.4%▲+0.73%×0.08

Q2 FY26—▼−0.06%—

= impliedALNY realized, solidXPO realized, hatchedOne scale, both sides: full bar = 29%× = |realized| ÷ impliedSource: market data

Q1 FY26

—

▲+1.58%

—

Feb 5 '26—▲+3.39%—

ALNYAlnylam Pharmaceuticals, Inc.

164.89▼−5.24%· post 165.53

Mkt cap$22.1BRevenue$1.5BQ3 FY26Revenue$3.7BFY25

XPOXPO, Inc.

189.61▲+3.61%· post 189.63

ClosedOct 30 '26

Mkt cap$22.1BRevenue$2.4BQ3 FY26Revenue$8.2BFY25

Compare

ClosedOct 30 '26

ALNYAlnylam Pharmaceuticals, Inc.

XPOXPO, Inc.

164.89▼−5.24%post 165.53

Price

189.61▲+3.61%post 189.63

$22.1B

Mkt cap

$22.1B

Q3 FY26$1.5B

Revenue

$2.4BQ3 FY26

FY25$3.7B

Revenue

$8.2BFY25

ALNY164.89▼−5.24%vsXPO189.61▲+3.61%ClosedOct 30 '26